Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies

International Journal of Biochemistry and Molecular Biology

Volumn 3, Issue 2, 2012, Pages 117-136

  Talbot, Lindsay J ^b   Bhattacharya, Syamal D ^b   Kuo, Paul C ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Epithelial mesenchymal transition; Metastasis; Prevention; Therapy; Tumor microenvironment

Indexed keywords

FRIZZLED PROTEIN; MICRORNA; NOTCH RECEPTOR; SECRETED FRIZZLED RELATED PROTEIN 5; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD7 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

APOPTOSIS; CANCER PREVENTION; CARCINOGENESIS; CARCINOMA; CELL HYPOXIA; CELL INVASION; CELL JUNCTION; CELL MOTILITY; CELL POLARITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; METASTASIS POTENTIAL; PHENOTYPE; PLASTICITY; PRIMARY TUMOR; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TRANSLATION REGULATION; TUMOR MICROENVIRONMENT;

EID: 84862495767     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Friedl P and Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 2009; 10: 445-457.
2. Hay ED. Interaction of embryonic surface and cytoskeleton with extracellular matrix. Am J Anat 1982; 165: 1-12.
3. Micalizzi DS, Farabaugh SM and Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15: 117-134.
4. Huang D and Du X. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol 2008; 14: 1823-1827.
5. Blobe GC, Schiemann WP and Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
6. Meulmeester E and Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol 2011; 223: 205-218.
7. Wendt MK, Tian M and Schiemann WP. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res 2012; 347: 85-101.
8. Koinuma D, Tsutsumi S, Kamimura N, Imamura T, Aburatani H and Miyazono K. Promoter-wide analysis of Smad4 binding sites in human epithelial cells. Cancer Sci 2009; 100: 2133-2142.
9. Tian M, Neil JR and Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951-962.
10. Levy L and Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41-58.
11. Ten Dijke P, Goumans MJ, Itoh F and Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002; 191: 1-16.
12. Postigo AA, Depp JL, Taylor JJ and Kroll KL. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J 2003; 22: 2453-2462.
13. Miettinen PJ, Ebner R, Lopez AR and Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2021-2036.
14. Xu J, Lamouille S and Derynck R. TGF-betainduced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
15. Leptin M. twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev 1991; 5: 1568-1576.
16. D'Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F and Coppa A. A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression. Endocr Relat Cancer 2012; 19: 39-55.
17. Mazur PK, Einwachter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Kloppel G, Schmid RM and Siveke JT. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2010; 107: 13438-13443.
18. Fuxe J, Vincent T and Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010; 9: 2363-2374.
19. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N and Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-tomesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer 2011; 105: 1885-1893.
20. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML and Arteaga CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007; 117: 1305-1313.
21. Zhou YC, Liu JY, Li J, Zhang J, Xu YQ, Zhang HW, Qiu LB, Ding GR, Su XM, Mei S and Guo GZ. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelialmesenchymal transition. Int J Radiat Oncol Biol Phys 2011; 81: 1530-1537.
22. Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther 2006; 5: 1059-1064.
23. Bovolenta P, Esteve P, Ruiz JM, Cisneros E and Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 2008; 121: 737-746.
24. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, Fearon ER and Weiss SJ. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 2006; 8: 1398-1406.
25. Gauger KJ, Chenausky KL, Murray ME and Schneider SS. SFRP1 reduction results in an increased sensitivity to TGF-beta signaling. BMC Cancer 2011; 11: 59.
26. Gauger KJ, Hugh JM, Troester MA and Schneider SS. Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer Cell Int 2009; 9: 11.
27. Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Liu HS, Chu DW and Lin YW. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol 2009; 112: 646-653.
28. Gerard B, Tait L, Nangia-Makker P and Shekhar MP. Rad6B acts downstream of Wnt signaling to stabilize beta-catenin: Implications for a novel Wnt/beta-catenin target. J Mol Signal 2011; 6: 6.
29. Iwai S, Yonekawa A, Harada C, Hamada M, Katagiri W, Nakazawa M and Yura Y. Involvement of the Wnt-beta-catenin pathway in invasion and migration of oral squamous carcinoma cells. Int J Oncol 2010; 37: 1095-1103.
30. Blavier L, Lazaryev A, Shi XH, Dorey FJ, Shackleford GM and DeClerck YA. Stromelysin-1 (MMP- 3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Can cer Biol Ther 2010; 10: 198-208.
31. Zhai Y, Iura A, Yeasmin S, Wiese AB, Wu R, Feng Y, Fearon ER and Cho KR. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma. Oncogene 2011; 30: 4152-4162.
32. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R and Ralhan R. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 2009; 9: 325.
33. Kwon CY, Kim KR, Choi HN, Chung MJ, Noh SJ, Kim DG, Kang MJ, Lee DG and Moon WS. The role of serum response factor in hepatocellular carcinoma: implications for disease progression. Int J Oncol 2010; 37: 837-844.
34. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH and Zi X. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010; 9: 162.
35. Zhao JH, Luo Y, Jiang YG, He DL and Wu CT. Knockdown of beta-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1alpha. Cancer Invest 2011; 29: 377-382.
36. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, Li MC and Lin YH. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007; 14: 1034-1039.
37. Chen YS, Mathias RA, Mathivanan S, Kapp EA, Moritz RL, Zhu HJ and Simpson RJ. Proteomics profiling of Madin-Darby canine kidney plasma membranes reveals Wnt-5a involvement during oncogenic H-Ras/TGF-beta-mediated epithelialmesenchymal transition. Mol Cell Proteomics 2011; 10: M110. 001131.
38. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S and Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelialmesenchymal transition in basal-like breast cancer. Cancer Res 2009; 69: 5364-5373.
39. Kurasawa Y, Kozaki K, Pimkhaokham A, Muramatsu T, Ono H, Ishihara T, Uzawa N, Imoto I, Amagasa T and Inazawa J. Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells. Oncogene 2012; 31: 1963-1974.
40. Heuberger J and Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol 2010; 2: a002915.
41. Doble BW and Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelialmesenchymal transitions. Cells Tissues Organs 2007; 185: 73-84.
42. Weerkamp F, van Dongen JJ and Staal FJ. Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia 2006; 20: 1197-1205.
43. Bolos V, Grego-Bessa J and de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007; 28: 339-363.
44. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D and Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806: 258-267.
45. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC and de la Pompa JL. Notch promotes epithelialmesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 2004; 18: 99-115.
46. Tseng YC, Tsai YH, Tseng MJ, Hsu KW, Yang MC, Huang KH, Li AF, Chi CW, Hsieh RH, Ku HH and Yeh TS. Notch2-induced COX-2 expression enhancing gastric cancer progression. Mol Carcinog 2011.
47. Sharma A, Paranjape AN, Rangarajan A and Dighe RR. A Monoclonal Antibody against Human Notch1 Ligand Binding Domain Depletes Subpopulation of Breast Cancer Stem-like Cells. Mol Cancer Ther 2012; 11: 77-86.
48. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ and Kurie JM. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR- 200-dependent pathway in mice. J Clin Invest 2011; 121: 1373-1385.
49. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L and Sarkar FH. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307: 26-36.
50. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J and Brabletz T. The ZEB1/miR- 200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011; 30: 770-782.
51. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
52. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A and Kikkawa F. Chemoresistance to paclitaxel induces epithelialmesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277-283.
53. Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T, Edwards R, Mayer NJ, Qazi H, Goyal S, Fernandez S, Straatman K, Jones GD, Bowman KJ, Colquhoun A, Mellon JK, Kriajevska M and Tulchinsky E. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA 2009; 106: 14884-14889.
54. Iseri OD, Kars MD, Arpaci F, Atalay C, Pak I and Gunduz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 2011; 65: 40-45.
55. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH. Acquisition of epithelialmesenchymal transition phenotype of gemcitabine- resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400-2407.
56. Gungor C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, Yekebas E and Bockhorn M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 2011; 71: 5009-5019.
57. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP and Tian Y. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 2012; 113: 1501-1513.
58. Sethi S, Macoska J, Chen W and Sarkar FH. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010; 3: 90-99.
59. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G and Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65: 8530-8537.
60. Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ and Siebold C. Interactions between Hedgehog proteins and their binding partners come into view. Genes Dev 2010; 24: 2001-2012.
61. Sarkar FH, Li Y, Wang Z and Kong D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev 2010; 29: 383-394.
62. Louro ID, Bailey EC, Li X, South LS, McKie-Bell PR, Yoder BK, Huang CC, Johnson MR, Hill AE, Johnson RL and Ruppert JM. Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res 2002; 62: 5867-5873.
63. Maitah MY, Ali S, Ahmad A, Gadgeel S and Sarkar FH. Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One 2011; 6: e16068.
64. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA and Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 2011; 55: 838-845.
65. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P and Ruiz i Altaba A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009; 1: 338-351.
66. Zheng X, Yao Y, Xu Q, Tu K and Liu Q. Evaluation of glioma-associated oncogene 1 expression and its correlation with the expression of sonic hedgehog, E-cadherin and S100a4 in human hepatocellular carcinoma. Mol Med Report 2010; 3: 965-970.
67. Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, Kim JS and Oh SC. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res 2011; 71: 7061-7070.
68. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL and Hong YR. Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep 2010; 24: 1225-1232.
69. Joost S, Almada LL, Rohnalter V, Holz PS, Vrabel AM, Fernandez-Barrena MG, McWilliams RR, Krause M, Fernandez-Zapico ME and Lauth M. GLI1 Inhibition Promotes Epithelial-to- Mesenchymal Transition in Pancreatic Cancer Cells. Cancer Res 2012; 72: 88-99.
70. Yang J and Weinberg RA. Epithelialmesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-829.
71. Peinado H, Olmeda D and Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428.
72. Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
73. Yook JI, Li XY, Ota I, Fearon ER and Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem 2005; 280: 11740-11748.
74. Kuphal S, Palm HG, Poser I and Bosserhoff AK. Snail-regulated genes in malignant melanoma. Melanoma Res 2005; 15: 305-313.
75. Ren D, Minami Y and Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snailmediated epithelial-mesenchymal transition. Genes Cells 2011; 16: 304-315.
76. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N and Kawakami Y. The mecha nisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 2011; 93: 294-300.
77. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U and Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-4271.
78. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF and Fuxe J. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial- mesenchymal transition. Nat Cell Biol 2009; 11: 943-950.
79. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
80. Li J and Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem celllike characters. BMC Cancer 2011; 11: 49.
81. Blokzijl A, Dahlqvist C, Reissmann E, Falk A, Moliner A, Lendahl U and Ibanez CF. Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J Cell Biol 2003; 163: 723-728.
82. Blumenberg M, Gao S, Dickman K, Grollman AP, Bottinger EP and Zavadil J. Chromatin structure regulation in transforming growth factorbeta- directed epithelial-mesenchymal transition. Cells Tissues Organs 2007; 185: 162-174.
83. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF and Goodall GJ. A doublenegative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial- mesenchymal transition. Cancer Res 2008; 68: 7846-7854.
84. Gregory PA, Bracken CP, Bert AG and Goodall GJ. MicroRNAs as regulators of epithelialmesenchymal transition. Cell Cycle 2008; 7: 3112-3118.
85. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y and Goodall GJ. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22: 1686-1698.
86. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S and Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495.
87. Mongroo PS and Rustgi AK. The role of the miR- 200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010; 10: 219-222.
88. Korpal M, Lee ES, Hu G and Kang Y. The miR- 200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
89. Ahn SM, Cha JY, Kim J, Kim D, Trang HT, Kim YM, Cho YH, Park D and Hong S. Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene 2011.
90. Zhang Z, Liu S, Shi R and Zhao G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet 2011; 204: 486-491.
91. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY and Yu MH. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010; 127: 555-567.
92. Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G and Ralhan R. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci 2008; 83: 318-325.
93. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M and Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 2008; 105: 14867-14872.
94. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM, Lenburg M and Thiagalingam S. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 2010; 70: 968-978.
95. Chaffer CL and Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
96. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW and Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGFmediated signaling networks. Oncogene 2005; 24: 5053-5068.
97. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002; 12: 89-96.
98. Kalluri R and Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
99. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK and Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725
100. Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong KL, Kwong DL and Guan XY. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/beta-catenin signalling pathway. Gut 2011; 60: 1635-1643.
101. Ungefroren H, Sebens S, Seidl D, Lehnert H and Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011; 9: 18.
102. Brabek J, Mierke CT, Rosel D, Vesely P and Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal 2010; 8: 22.
103. Leight JL, Wozniak MA, Chen S, Lynch ML and Chen CS. Matrix rigidity regulates a switch between TGF-beta1-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell 2012; 23: 781-791.
104. Avni R, Cohen B and Neeman M. Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. NMR Biomed 2011; 24: 569-581.
105. Cannito S, Novo E, Compagnone A, Valfre di Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, Cravanzola C, Bravoco V, Colombatto S and Parola M. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008; 29: 2267-2278.
106. Sahlgren C, Gustafsson MV, Jin S, Poellinger L and Lendahl U. Notch signaling mediates hypoxia- induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008; 105: 6392-6397.
107. Kim HM, Haraguchi N, Ishii H, Ohkuma M, Okano M, Mimori K, Eguchi H, Yamamoto H, Nagano H, Sekimoto M, Doki Y and Mori M. Increased CD13 Expression Reduces Reactive Oxygen Species, Promoting Survival of Liver Cancer Stem Cells via an Epithelial- Mesenchymal Transition-like Phenomenon. Ann Surg Oncol 2011.